-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Helicobacter pylori Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Helicobacter pylori Infections - Drugs In Development, 2023’, provides an overview of the Helicobacter pylori Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pandemic Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Pandemic Influenza - Drugs In Development, 2023’, provides an overview of the Pandemic Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pandemic Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Monkeypox – Drugs In Development, 2023
Global Markets Direct’s, ‘Monkeypox - Drugs In Development, 2023’, provides an overview of the Monkeypox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Monkeypox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADS-024 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADS-024 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details: ART-24 (ADS-024) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strain A/H7N9] Vaccine in Influenza A Virus, H7N9 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [Strain A/H7N9] Vaccine in Influenza A Virus, H7N9 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Influenza [Strain A/H7N9] Vaccine in Influenza...
-
Company Profile
EpiVax Inc – Company Profile
EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T cells. It is an immune-modulation power tool that is being developed for auto-immune, auto-inflammatory and allergic conditions. EpiVax’ service portfolio includes immune engineering, immunogenicity screening, vaccine design, and redesign. The company also provides lab services such as in vivo, in...
Add to Basket -
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...
-
Product Insights
Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Report Overview Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia, and general malaise. Treatment includes antiviral drugs. The Influenza A Virus, H7N9 Subtype Infections pipeline drugs market research report provides comprehensive information on the Influenza A Virus,...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Cytotoxic T-cell based cancer immunotherapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Cytotoxic T-cell based cancer immunotherapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...